-+ 0.00%
-+ 0.00%
-+ 0.00%

Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027

Benzinga·10/29/2026 12:10:04
Listen to the news
  • Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS <1 and the neoadjuvant setting of STS, with preparations for future clinical trials underway and study start targeted for H2 CY27.
  • IMP761, the Company's agonist anti-LAG-3 antibody for autoimmune diseases, is now a co-priority alongside efti and will be the subject of a late breaking poster at the American College of Rheumatology (ACR) Convergence in November 2026.
  • The ongoing root cause analysis following the discontinuation of TACTI-004 has identified structural differences between the 2000 L scale efti used in TACTI-004 and the 200 L scale efti used in earlier successful clinical studies. A new manufacturing run of efti at 200 L scale has been contracted.
  • The Company received an A$0.86 million cash rebate under the Australian Government’s R&D Tax Incentive for eligible FY2025 R&D activities and, subsequent to the end of the quarter, €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche (CIR) program for eligible CY2025 R&D activities.
  • Cash and term deposits of A$48.50 million at 30 September 2026, with cash runway expected to extend well into H1 CY28.